Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

被引:74
作者
LoRusso, Patricia M. [2 ]
Edelman, Martin J. [1 ]
Bever, Susan L. [3 ]
Forman, Karen M. [2 ]
Pilat, MaryJo [2 ]
Quinn, Mary F. [1 ]
Li, Jing [2 ]
Heath, Elisabeth I. [2 ]
Malburg, Lisa M. [2 ]
Klein, Patrick J. [3 ]
Leamon, Christopher P. [3 ]
Messmann, Richard A. [3 ]
Sausville, Edward A. [1 ]
机构
[1] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[3] Endocyte, W Lafayette, IN USA
关键词
GENERATION; BINDING;
D O I
10.1200/JCO.2011.41.4946
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors. Patients and Methods EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle with dose escalation in cohorts of three to six patients until the MTD was identified. Plasma pharmacokinetics were determined on days 1 and 3 of the first cycle. Results The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion. Constipation was the dose-limiting toxicity with both routes. Constipation, nausea, fatigue, and vomiting were the most commonly reported adverse events. One partial response to therapy was observed in a patient with metastatic ovarian cancer. Conclusion EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer. On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer. J Clin Oncol 30:4011-4016. (C) 2012 by American Society of Clinical Oncology
引用
收藏
页码:4011 / 4016
页数:6
相关论文
共 22 条
[1]  
[Anonymous], COMM TERM CRIT ADV E
[2]   Caveolae - An alternative endocytotic pathway for targeted drug delivery [J].
Bathori, G ;
Cervenak, L ;
Karadi, I .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (02) :67-95
[3]   Toxicity patterns of cytotoxic drugs [J].
Chatelut, E ;
Delord, JP ;
Canal, P .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) :141-148
[4]   A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies [J].
Fanale, Michelle A. ;
Forero-Torres, Andres ;
Rosenblatt, Joseph D. ;
Advani, Ranjana H. ;
Franklin, Anna R. ;
Kennedy, Dana A. ;
Han, Tae H. ;
Sievers, Eric L. ;
Bartlett, Nancy L. .
CLINICAL CANCER RESEARCH, 2012, 18 (01) :248-255
[5]   Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors [J].
Fisher, Ronald E. ;
Siegel, Barry A. ;
Edell, Steven L. ;
Oyesiku, Nelson M. ;
Morgenstern, David E. ;
Messmann, Richard A. ;
Amato, Robert J. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (06) :899-906
[6]   Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145 [J].
Leamon, Christopher P. ;
Reddy, Joseph A. ;
Vlahov, Lontcho R. ;
Westrick, Elaine ;
Parker, Nikki ;
Nicoson, Jeffrey S. ;
Vetzel, Marilynn .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (07) :1585-1592
[7]   Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications [J].
Leamon, Christopher P. ;
Reddy, Joseph A. ;
Klein, Patrick J. ;
Vlahov, Iontcho R. ;
Dorton, Ryan ;
Bloomfield, Alicia ;
Nelson, Melissa ;
Westrick, Elaine ;
Parker, Nikki ;
Bruna, Kristen ;
Vetzel, Marilynn ;
Gehrke, Mark ;
Nicoson, Jeffrey S. ;
Messmann, Richard A. ;
LoRusso, Patricia M. ;
Sausville, Edward A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (02) :336-343
[8]  
Lemke T, 2008, CANC CHEMOTHERAPY FO, P1184
[9]   Clinical Pharmacokinetics and Exposure-Toxicity Relationship of a Folate-Vinca Alkaloid Conjugate EC145 in Cancer Patients [J].
Li, Jing ;
Sausville, Edward A. ;
Klein, Patrick J. ;
Morgenstern, David ;
Leamon, Christopher P. ;
Messmann, Richard A. ;
LoRusso, Patricia .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12) :1467-1476
[10]   Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer [J].
LoRusso, Patricia M. ;
Weiss, Denise ;
Guardino, Ellie ;
Girish, Sandhya ;
Sliwkowski, Mark X. .
CLINICAL CANCER RESEARCH, 2011, 17 (20) :6437-6447